Skip to content

Study · Animal study (in vivo) · rat · 2000

6 results

Polaprezinc exerts a salutary effect on impaired healing of acute gastric lesions in diabetic rats.

Korolkiewicz RP, Fujita A, Seto K, Suzuki K, Takeuchi K

Digestive diseases and sciences1 Jun 2000Cited by 12 (Europe PMC)

PMID10877238 (opens in a new tab)DOI10.1023/a:1005566406257 (opens in a new tab)PepBankPUB-10877238
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, L‑carnosine alone did not show the reported trend toward improved gastric lesion healing.

    In plain wordsIn rats with diabetes, L‑carnosine alone did not show the reported trend toward improved stomach lesion healing.

    Peptide
    L-carnosine
    Outcome
    No significant changeGastric lesion healing with L-carnosine alone
    Study

    ratn: not reported in source

    streptozotocin-diabetic rats with HCl-induced gastric lesions
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · oral · four daysAs given in this study (rat).

    Source sentences

    Summary
    Similar trends were observed with ZnSO4/7H2O or a mixture of ZnSO4/7H2O and L-carnosine, but not by L-carnosine alone.
    3 context sentences
    Summary · context
    Polaprezinc (>10 mg/kg) significantly reversed the delay observed in diabetic rats without any notable effects on BGLs or acid secretion.
    Summary · context
    Studies were performed on rats injected intraperitoneally with streptozotocin (STZ, 70 mg/kg) five weeks prior to experiments.
    Summary · context
    Polaprezinc (3-30 mg/kg) or its components ZnSO4/7H2O and L-carnosine were given orally, twice daily for four days following HCl treatment.

Studies that did not test the peptide alone5

In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking L-carnosine.

  1. 02AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, polaprezinc significantly reversed delayed gastric lesion healing.

    In plain wordsIn rats with diabetes, polaprezinc significantly reduced delayed stomach lesion healing.

    Peptide
    L-carnosine
    Outcome
    DecreaseGastric lesion healing delay
    Study

    ratn: not reported in source

    streptozotocin-diabetic rats with HCl-induced gastric lesions
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    Polaprezinc (>10 mg/kg) significantly reversed the delay observed in diabetic rats without any notable effects on BGLs or acid secretion.
    2 context sentences
    Summary · context
    Studies were performed on rats injected intraperitoneally with streptozotocin (STZ, 70 mg/kg) five weeks prior to experiments.
    Summary · context
    Polaprezinc (3-30 mg/kg) or its components ZnSO4/7H2O and L-carnosine were given orally, twice daily for four days following HCl treatment.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  2. 03AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, polaprezinc had no notable effect on blood glucose.

    In plain wordsIn rats with diabetes, polaprezinc had no notable effect on blood glucose.

    Peptide
    L-carnosine
    Outcome
    No significant changeBlood glucose
    Study

    ratn: not reported in source

    streptozotocin-diabetic rats with HCl-induced gastric lesions
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Polaprezinc (>10 mg/kg) significantly reversed the delay observed in diabetic rats without any notable effects on BGLs or acid secretion.
    2 context sentences
    Summary · context
    Studies were performed on rats injected intraperitoneally with streptozotocin (STZ, 70 mg/kg) five weeks prior to experiments.
    Summary · context
    Polaprezinc (3-30 mg/kg) or its components ZnSO4/7H2O and L-carnosine were given orally, twice daily for four days following HCl treatment.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  3. 04AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, polaprezinc had no notable effect on acid secretion.

    In plain wordsIn rats with diabetes, polaprezinc had no notable effect on stomach acid secretion.

    Peptide
    L-carnosine
    Outcome
    No significant changeAcid secretion
    Study

    ratn: not reported in source

    streptozotocin-diabetic rats with HCl-induced gastric lesions
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    Polaprezinc (>10 mg/kg) significantly reversed the delay observed in diabetic rats without any notable effects on BGLs or acid secretion.
    2 context sentences
    Summary · context
    Studies were performed on rats injected intraperitoneally with streptozotocin (STZ, 70 mg/kg) five weeks prior to experiments.
    Summary · context
    Polaprezinc (3-30 mg/kg) or its components ZnSO4/7H2O and L-carnosine were given orally, twice daily for four days following HCl treatment.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  4. 05AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, a zinc sulfate and L‑carnosine mixture showed a similar trend toward improved gastric lesion healing.

    In plain wordsIn rats with diabetes, a zinc sulfate and L‑carnosine mixture showed a similar trend toward improved stomach lesion healing.

    Peptide
    L-carnosine
    Outcome
    IncreaseGastric lesion healing with zinc-carnosine mixture
    Study

    ratn: not reported in source

    streptozotocin-diabetic rats with HCl-induced gastric lesions
    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    Similar trends were observed with ZnSO4/7H2O or a mixture of ZnSO4/7H2O and L-carnosine, but not by L-carnosine alone.
    3 context sentences
    Summary · context
    Polaprezinc (>10 mg/kg) significantly reversed the delay observed in diabetic rats without any notable effects on BGLs or acid secretion.
    Summary · context
    Studies were performed on rats injected intraperitoneally with streptozotocin (STZ, 70 mg/kg) five weeks prior to experiments.
    Summary · context
    Polaprezinc (3-30 mg/kg) or its components ZnSO4/7H2O and L-carnosine were given orally, twice daily for four days following HCl treatment.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  5. 06AnimalNot a test of L-carnosine aloneAnimal study (in vivo)Mechanism

    In diabetic rats, polaprezinc partially corrected reduced gastric mucosal IGF-I mRNA expression.

    In plain wordsIn rats with diabetes, polaprezinc partially corrected reduced IGF-I gene expression in the stomach lining.

    Peptide
    L-carnosine
    Outcome
    IncreaseGastric mucosal IGF-I mRNA
    Study

    ratn: not reported in source

    streptozotocin-diabetic rats with HCl-induced gastric lesions
    Outcome group
    Growth hormone and IGF-1 · Gastrointestinal

    Source sentences

    Summary
    The mucosal expression of insulin-like growth factor-1 (IGF-I) mRNA was significantly lower in diabetic rats, a dysregulation partially corrected by insulin and polaprezinc.
    2 context sentences
    Summary · context
    Studies were performed on rats injected intraperitoneally with streptozotocin (STZ, 70 mg/kg) five weeks prior to experiments.
    Summary · context
    Polaprezinc (3-30 mg/kg) or its components ZnSO4/7H2O and L-carnosine were given orally, twice daily for four days following HCl treatment.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.